Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Breadcrumb

  1. Home
  2. Vantage
  3. Pharmaceutical Companies
  4. Kissei Pharmaceutical
March 14, 2023

Morphic looks to justify “oral Entyvio” excitement

Big hopes have built behind Morphic’s MORF-057 in ulcerative colitis, and a key trial reads out imminently.

Thumbnail
March 21, 2022

Biohaven’s high-risk bet

There are long shots and then there is troriluzole. Biohaven will soon find out if it was wise to press on with the asset.

Article image
Vantage logo
March 01, 2021

Early Morphic data hint at a threat to Entyvio

Hopes rise that Morphic might have cracked the conundrum of oral integrin inhibitors.

Article image
Vantage logo
December 06, 2018

Bayer puts the brakes on vilaprisan trials following safety concerns

The decision to halt trials for the uterine fibroid product marks another setback in an area where there are few suitable solutions for patients.

Article image
Vantage logo
October 19, 2018

Abbvie makes a big bet on preclinical integrin inhibitors

Vantage logo
October 04, 2017

Therapy focus – No safe haven for bio in spinocerebellar ataxia

Vantage logo
May 19, 2015

Dry eye development reaches the Eleventh hour

Vantage logo
April 23, 2015

GSK labours the point of addressing the unloved unmet needs

Vantage logo
August 06, 2014

Waiting game continues with Mircera launch

Vantage logo
January 03, 2014

Pharma business development news over Christmas

Vantage logo
March 05, 2013

Lexicon could define Sanofi as the ideal diabetes partner

  • Load More
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

February 17, 2023

PD(L)anner – February 2023

February 09, 2023

Biopharma and Medtech Review 2022

View more...

Editor's Picks

Vantage logo
March 13, 2023

Silicon Valley Bank: biopharma’s latest crisis

Vantage logo
March 13, 2023

Pfizer rescues biotech

Vantage logo
February 28, 2023

Why Pfizer (and others) will be interested in Seagen

Vantage logo
March 04, 2023

ACC 2023 – Esperion’s outcomes win looks lacklustre

Vantage logo
March 06, 2023

T-cell receptor behemoths consolidate? Not quite

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-80-1164-4754

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy
  • Modern Slavery Statement

© Copyright 2023 Evaluate Ltd.

Sign up